Minervax

About:

Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.

Top Investors: European Investment Bank, OrbiMed, Novo Holdings, Wellington Partners, EQT Life Sciences

Description:

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Total Funding Amount:

$215M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Hellerup, Hovedstaden, Denmark

Founded Date:

2010-01-01

Contact Email:

pbf(AT)minervax.com

Founders:

Per Fischer

Number of Employees:

1-10

Last Funding Date:

2023-10-11

IPO Status:

Private

Industries: